<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03372356</url>
  </required_header>
  <id_info>
    <org_study_id>PSNET</org_study_id>
    <nct_id>NCT03372356</nct_id>
  </id_info>
  <brief_title>Psychosocial Screening for Neuroendocrine Tumor Patients</brief_title>
  <official_title>Psychosocial Screening for Neuroendocrine Tumor Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a psychosocial screening application to usual care in a cohort of neuroendocrine
      tumor patients. The application involves monitoring using the NCCN Distress Thermometer(DT),
      Hospital Anxiety and Depression Scale(HADS), Self-Perceived Burden Scale(SPBS) and
      Connor-Davidson Resilience Scale(CD-RISC). These assessments will be completed at baseline, 3
      months, 6 months, 12 months and 24 months. Patients will have the option of filling out
      questionnaires more frequently if desired.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 9, 2017</start_date>
  <completion_date type="Anticipated">August 9, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 9, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DT</measure>
    <time_frame>every 3 month until 24 month</time_frame>
    <description>Distress Thermometer</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HADS</measure>
    <time_frame>every 3 month until 24 month</time_frame>
    <description>Hospital Anxiety and Depression Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SPBS</measure>
    <time_frame>every 3 month until 24 month</time_frame>
    <description>Self-Perceived Burden Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD-RISC</measure>
    <time_frame>every 3 month until 24 month</time_frame>
    <description>Connor-Davidson Resilience Scale</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Neuroendocrine Tumors</condition>
  <arm_group>
    <arm_group_label>Neuroendocrine tumors</arm_group_label>
    <description>Patients with neuroendocrine tumors will be given access to an application that monitors distress, anxiety, depression, self-perceived burden, and resilience at regular intervals for 3 months lasting for 24 months.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with well-differentiated neuroendocrine tumors, G1-2 (Ki67≤20%)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. sign written informed consent form;

          2. age ≥ 18 years;

          3. pathologically confirmed well-differentiated neuroendocrine tumors, G1-2 (Ki67≤20%);

        Exclusion Criteria:

          1. &lt;18 years;

          2. Neuroendocrine carcinoma;

          3. History of psychiatric or psychologic illness;

          4. History of previous cancers or cancer distress;

          5. Patients with central nervous system(CNS) disorder；

          6. Severe, uncontrolled medical condition that would affect patients' compliance;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shen Lin, Professor</last_name>
      <phone>010-88196561</phone>
      <email>Linshenpku@163.com</email>
    </contact>
    <investigator>
      <last_name>Shen Lin, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2017</study_first_submitted>
  <study_first_submitted_qc>December 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2017</study_first_posted>
  <last_update_submitted>December 10, 2017</last_update_submitted>
  <last_update_submitted_qc>December 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital</investigator_title>
  </responsible_party>
  <keyword>DT</keyword>
  <keyword>HADS</keyword>
  <keyword>SPBS</keyword>
  <keyword>CD-RISC</keyword>
  <keyword>Psychosocial Screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

